7 Notable Companies Advancing Women’s Health with AI
Back in 2016, Ida Tin, the CEO behind the renowned period-tracking app Clue, introduced the term "FemTech" to capture the wave of startups pushing the boundaries of technology in the realm of female health. Today, the term encompasses an even wider range of innovative solutions aimed at enhancing every aspect of women's lives.
Femtech addresses health needs that have been underfunded and understudied for decades, serving roughly half the world’s population while historically receiving less attention in research design, diagnostics, and care pathways. The consequences show up across everyday medicine—underdiagnosis of pelvic pain, limited options for menopause care, gaps in maternal health, and sparse tooling for clinicians.
Femtech companies are beginning to bridge these systemic gaps by translating women’s lived experiences and unmet clinical needs into measurable design and data priorities. Technologies range from wearables and software to non-invasive devices and AI/ML models that support screening, triage, reporting, decision support, and longitudinal disease management. The market is moving towards regulated, clinically validated tools with clear safety, privacy, and data-governance practices.
The rise of femtech displays a broader correction in healthcare—recognizing women’s health as central, not secondary. It is about building tools that address real clinical gaps, from reproductive care to chronic pain and menopause. Below are seven companies using AI to tackle these long-neglected areas of women’s health with evidence-based, practical solutions.
1. Ava
Ava is the ideal companion for women who are trying to get pregnant and want to make the most of their chances to conceive, as well as for women who want to get to know their bodies and cycle better.
Ava Fertility is a clinically validated wearable and mobile platform designed to help women identify their fertile window in real time. The Ava bracelet, an FDA-registered and CE-certified device, continuously monitors multiple physiological parameters during sleep (e.g., skin temperature, resting pulse rate, breathing rate, heart rate variability) to detect hormonal changes associated with different phases of the menstrual cycle. It then processes multi-parametric signals with machine-learning algorithms to identify the fertile window. The device was clinically tested in a year-long study at the University Hospital of Zurich.
Each morning, users sync the bracelet with the companion app to access an analysis of their fertility status, providing visibility into five out of six fertile days per cycle—reportedly up to four days earlier and with greater precision than standard ovulation or calendar-based tracking methods. Beyond fertility monitoring, the Ava platform also tracks sleep, stress, and pregnancy trends, offering a continuous overview of reproductive and general health through data-driven insights accessible on both iOS and Android devices.
During the COVID-19 pandemic, the Ava bracelet was tested for infection screening in the Liechtenstein COVI-GAPP cohort and in the large randomized COVID-RED trial. Peer-reviewed reports describe nightly measurements (respiratory rate, heart rate, HRV, wrist-skin temperature, skin perfusion) and show that an algorithm using these signals and symptom diaries produced earlier alerts than symptom-only screening.
The company has raised a total of $42.3 million in funding over 8 rounds, with their latest $30M raised in May 2018 from a Series B round.
2. Bloomlife
Bloomlife develops prenatal care solutions designed to improve the health of moms and babies. The company's solutions combine pregnancy-specific wearables with data analytics to reassure moms and provide doctors with better data to predict and manage pregnancy complications earlier.
Bloomlife MFM-Pro is a maternal-fetal monitoring system prescription, a single-use, non-invasive patch used late in pregnancy (≈32+ weeks) that measures fetal heart rate (FHR) and maternal heart rate (MHR). A reportedly short recording (about 12 minutes) is uploaded and a 5-minute fetal/maternal heart-rate strip is generated for review. The system is FDA 510(k)–cleared for antepartum monitoring of fetal and maternal heart rate.
Bloomlife partnered with PeriGen in early 2024 to integrate machine learning–driven analytics into remote maternal health monitoring. The collaboration connects Bloomlife’s at-home prenatal wearable with PeriGen’s PeriWatch Vigilance software, which applies AI and advanced statistical models to analyze real-time patterns and flag potential complications.
Bloomlife’s $12.2 million Series A round, announced in September 2024, followed FDA clearance of its MFM-Pro maternal–fetal monitoring patch and is funding both the device’s commercial rollout and development of a second, as-yet-unnamed wearable to extend the company’s remote maternal-care and machine-learning analytics platform.
3. Flo
Flo Health is an AI-powered women’s health platform that encompasses accurate cycle predictions, personalized daily health insights, and a closed, secure community of experts and peers. Flo meets the needs of women of all ages and goals—from periods to menopause, from pregnant women to young moms—and is truly a one-stop health solution for women during an entire reproductive cycle. In July 2025, Flo expanded beyond cycle tracking with a perimenopause module and continued to lean on ML-driven personalization.
Flo’s new Perimenopause module integrates research-based education, symptom tracking, and algorithmic assessment into its existing health platform. The feature provides users with a Perimenopause Score—a digitally validated tool that evaluates symptom patterns and life impact—alongside adaptive cycle predictions that reflect hormonal variability typical of this stage. Users can log and analyze changes like hot flashes, mood shifts, or sleep disturbances, receiving daily expert-verified insights tailored to their logged data.
Earlier, Flo Health raised over $200 million in a Series C round led by General Atlantic, becoming the first purely digital women’s health platform to reach unicorn valuation. The funding supports expansion of Flo’s AI- and data-driven health insights, broadening the app’s scope beyond menstrual and fertility tracking into perimenopause and menopause.
Flo Health is available as a free and premium app on both iOS and Android, accessible through the App Store and Google Play.
4. Sonio
Paris-based Sonio develops AI software for prenatal ultrasound—real-time image-quality checks, view/structure detection, and decision support for suspected fetal anomalies.
Sonio’s platform centers on two FDA-cleared modules Sonio Detect uses machine-learning to identify required fetal views/structures and verify image adequacy during acquisition and interpretation. Sonio Suspect assists interpreting physicians by automatically flagging and characterizing abnormal findings on detected views. Both are cleared as concurrent reading aids.
The software plugs into cloud reporting and image-management workflows, with an on-prem “edge” option for DICOM ingestion. In early 2025 the company introduced Sonio Voice, a voice-driven reporting add-on highlighted around the SMFM 2025 meeting.
In January 2024, Pediatrix Medical Group, a U.S. provider of maternal–fetal medicine services, implemented Sonio’s AI-powered prenatal ultrasound reporting and image management platform at its San Jose, California practice. The cloud-based system integrates with EHR, billing, and PACS systems to streamline ultrasound workflows and improve quality assurance.
Earlier, Samsung Medison has acquired Sonio, following approval from France’s Ministry of the Economy and Finance, to integrate Sonio’s AI-driven maternal ultrasound technology with its own imaging portfolio.
Sonio’s latest round was a $14 million Series A in July 2023, led by Cross Border Impact Ventures, following a €10 million EIC Accelerator award in 2022.
5. Mirvie
Preeclampsia is a pregnancy-specific hypertensive disorder defined by new-onset high blood pressure after 20 weeks (and sometimes postpartum) with proteinuria or other organ-involvement; globally it occurs in roughly 2-8% of pregnancies, and recent U.S. estimates place prevalence of 1 in 12 women having experienced it.
It can arise without warning and is associated with poor fetal growth, preterm birth and NICU admission, and maternal complications including headaches, seizures (eclampsia), and organ injury, with elevated long-term cardiovascular risk after the affected pregnancy.
San-Francisco based Mirvie develops RNA-based blood tests that aim to predict pregnancy complications months before symptoms, such as preeclampsia. The company’s platform analyzes cell-free RNA from the pregnant individual, placenta, and fetus and applies machine-learning models to stratify risk and support earlier, targeted care.
Launched in May 2025, Mirvie’s Encompass is a prenatal risk-stratification service for preeclampsia that pairs a cfRNA blood test with a preventive action plan and a virtual assistant. An at-home sample is collected between 18–22 weeks’ gestation; machine-learning models analyze placental and pregnancy cfRNA signals to estimate individualized risk, with results returned to the patient and care team in 10–14 days.
The company reports that, in studies powered by its Mirvie RNA Platform (~11,000 pregnancies), the test identified ~9/10 pregnancies that later developed preterm preeclampsia as high risk and that a low-risk result had a 99.7% probability of not developing preterm preeclampsia. The U.S. launch uses telehealth review and mobile phlebotomy, and is initially available for expectant patients ≥35 years at delivery without pre-existing high-risk conditions.
Recently, Mirvie and Advantia Health have launched a year-long U.S. pilot program using the Encompass RNA test to identify pregnant patients at high or low risk for preeclampsia.
WIN has also recently expanded its WINMaternity program through a partnership with Mirvie, integrating the Encompass RNA test alongside 24/7 nurse advocacy, virtual specialist access, and personalized interventions aimed at improving maternal health outcomes across its nationwide benefits platform.
6. Delfina Care
Another San-Francisco based company Delfina Care builds an AI-powered pregnancy care platform that analyzes EHR and remote-monitoring data to help care teams identify patients at elevated risk (e.g., hypertensive disorders) earlier and coordinates proactive interventions.
Delfina offers a machine learning–powered maternal care platform that connects pregnant patients with their clinical teams through continuous data monitoring and personalized support. The system integrates wearable and app-based tracking (e.g., vital signs, blood pressure, glucose, weight, symptoms, mood) with predictive analytics that flag early risks for complications such as preeclampsia or gestational diabetes.
Data flow into a provider dashboard, giving obstetric clinicians real-time insights to guide interventions and reduce unnecessary visits. Patients access telehealth services for nutrition, mental health, lactation, and exercise, alongside virtual “Delfina Guides” and group classes for ongoing education and support during pregnancy and up to six months postpartum.
Delfina Care has recently established partnerships with CareFirst BlueCross BlueShield Community Health Plan Maryland, Legacy Community Health, and the UnitedHealthcare Community Plan of Texas to expand access to its maternal health platform across Medicaid and community care networks in multiple states.
7. Anya
Breastfeeding can present challenges for many women during their parenting journey. Driven by innovation and empathy, UK-based Anya, formerly known as LatchAid, steps in as a comprehensive breastfeeding and early parenthood support app.
Leveraging 3D interactive and artificial intelligence technology, Anya assists mothers and expectant mothers with essential breastfeeding skills. Through touch-screen control of camera angles, the app showcases different breastfeeding positions, ensuring a personalized and interactive learning experience.
Additionally, Anya fosters a sense of community, allowing users to connect with others and share valuable support and advice. In 2023, the company joined the NHS accelerator to scale up its breastfeeding support app across the NHS.
Recently, a survey conducted by Health Innovation West of England and the Gloucestershire Local Maternity and Neonatal System assessed NHS maternity staff readiness for implementing Anya.
Following the survey, NHS Greater Manchester has partnered with Anya to provide all new parents in Greater Manchester and eastern Cheshire with free premium access to the app, offering 24/7 AI-assisted and specialist-supported guidance on infant feeding, including interactive 3D breastfeeding tutorials and evidence-based virtual support.
Anya is available via the App Store or Google Play.
Topic: AI in Bio
